CA
NZ
UK
AU
IND
US
● cbdMD reported 19% year-over-year net sales growth for the fiscal second quarter ended March 31, 2026, aided by its Bluebird Botanicals acquisition and a new Medicare benefit pathway, even as the company disclosed going-concern doubt and just $2.64 million in cash.
● Chemomab Therapeutics has agreed to merge with private precision-medicine firm Scipher Medicine, redirecting its anti-CCL24 antibody nebokitug from a liver-disease pipeline toward an AI-guided Phase 2 rheumatoid arthritis trial, backed by a $30 million private placement and a targeted fourth-quarter 2026 close.
● Citius Oncology, the roughly 71%-owned subsidiary of Citius Pharmaceuticals, reported $5.6 million in first-half fiscal 2026 LYMPHIR revenue and near-universal commercial payer coverage, even as both companies lean on recent financings to fund operations only through November 2026.
● 60 Degrees Pharmaceuticals nears interim data from a placebo-controlled babesiosis trial due by October 2026, a potential new use for its FDA-approved malaria drug tafenoquine, even as the company fights a Nasdaq delisting notice and reports going-concern doubt in its latest filings.
● Azitra is redirecting capital from its lead Netherton syndrome trial toward a new cosmetic ingredient program, even as the company fights an NYSE American delisting deadline and a large warrant overhang.
● Beyond Air closed fiscal 2026 with revenue up 107% and announced a new financing worth up to $30.1 million, even as the company races to satisfy a July 31 Nasdaq bid-price deadline following a 1-for-20 reverse split.
● BioAtla has hired a financial advisor to explore selling or licensing its Conditionally Active Biologic pipeline, cut roughly 70% of its workforce, and executed a 50-for-1 reverse split, after cash fell to $7.1 million at year-end 2025 and Nasdaq compliance came under threat.
● BioCardia says the FDA has confirmed its ongoing CardiAMP HF II trial may support Premarket Approval for its heart-failure cell therapy, but the company also disclosed a Nasdaq equity-deficiency notice and a going-concern warning before raising $4.4 million in early June.
● Biofrontera Inc., the US commercial dermatology company behind the Ameluz photodynamic therapy system, reported first-quarter 2026 revenue growth of 17% and gross margin near 80%, while awaiting an FDA decision on a new skin-cancer indication.
● BioVie's bezisterim faces two Phase 2 data readouts in early Parkinson's disease and long COVID within months, even as cash has fallen to roughly $13.1 million and auditors have flagged going-concern doubt about the clinical-stage biotech's finances.
Please wait processing your request...